Find Radio Compass News for Ulixertinib

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 869886-67-9, Vrt752271, Bvd-523, Ulixertinib [inn], Ulixertinib (bvd-523), Bvd-erk
Molecular Formula
C21H22Cl2N4O2
Molecular Weight
433.3  g/mol
InChI Key
KSERXGMCDHOLSS-LJQANCHMSA-N
FDA UNII
16ZDH50O1U

Ulixertinib
Ulixertinib is an orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.
1 2D Structure

Ulixertinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
2.1.2 InChI
InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
2.1.3 InChI Key
KSERXGMCDHOLSS-LJQANCHMSA-N
2.1.4 Canonical SMILES
CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl
2.1.5 Isomeric SMILES
CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl
2.2 Other Identifiers
2.2.1 UNII
16ZDH50O1U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bvd-523

2. Vrt752271

2.3.2 Depositor-Supplied Synonyms

1. 869886-67-9

2. Vrt752271

3. Bvd-523

4. Ulixertinib [inn]

5. Ulixertinib (bvd-523)

6. Bvd-erk

7. 16zdh50o1u

8. Chembl3590106

9. Ulixertinib (inn)

10. 869886-67-9 (free Base)

11. Vrt-752271

12. Ulixertinib (bvd-523, Vrt752271)

13. 1h-pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-n-((1s)-1-(3-chlorophenyl)-2-hydroxyethyl)-

14. N-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide

15. (s)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-(1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide

16. (s)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-(1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide.

17. 4-[5-chloranyl-2-(propan-2-ylamino)pyridin-4-yl]-~{n}-[(1~{s})-1-(3-chlorophenyl)-2-oxidanyl-ethyl]-1~{h}-pyrrole-2-carboxamide

18. Unii-16zdh50o1u

19. Ulixertinib (bvd-523,vrt752271)

20. 4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-((s)-1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide

21. Bvd523 Hcl

22. Bvd-523 Hcl

23. Ulixertinib [who-dd]

24. Vrt752271 Hcl

25. Gtpl9210

26. Schembl14211742

27. Dtxsid601025683

28. Bcp04232

29. Ex-a1332

30. Bdbm50094465

31. Nsc797771

32. Nsc800959

33. S7854

34. Zinc34642570

35. Akos025396467

36. Ccg-269049

37. Db13930

38. Nsc-797771

39. Nsc-800959

40. Ncgc00378692-02

41. Ncgc00378692-05

42. Ncgc00378692-07

43. Ac-33165

44. As-56114

45. Hy-15816

46. Bcp0726000085

47. D11038

48. J-690368

49. Q27089081

50. 3,5-dichloro-2-hydroxy-n-(4-methoxy-3-biphenylyl)benzenesulfonamide

51. 4-[5-chloro-2-(isopropylamino)-4-pyridinyl]-n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-1h-pyrrole-2-carboxamide

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 433.3 g/mol
Molecular Formula C21H22Cl2N4O2
XLogP34.1
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count4
Rotatable Bond Count7
Exact Mass432.1119813 g/mol
Monoisotopic Mass432.1119813 g/mol
Topological Polar Surface Area90 Ų
Heavy Atom Count29
Formal Charge0
Complexity539
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty